Company Analysis
Sign in

Valneva SE (VALN)

Nasdaq: VALN · Biological Products, (No Diagnostic Substances) · Saint-Herblain, FR · filing with the SEC since 2021
Full chart Alerts Compare
Grade4.6
◀ Past 6.2● Present 4.3▶ Future 3.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

68 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Valneva SE’s names, not what it holds today.

Patents granted
68
68 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 8 in 2024 and 3 in 2023
Applications published
77
6 of them in 2025
Names they are printed under
6
a subsidiary, its own name
By yearGrantedApplications published
'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals27
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
Valneva Austria GmbH a subsidiary
AT, as the owner printed on each patent. 3 more under the same name are not counted (printed in AU)
45 granted
45 published
Valneva SE its own name
FR, as the owner printed on each patent
13 granted
18 published
VALNEVA its own name
FR, as the owner printed on each patent
10 granted
6 published
Valneva Austria GmbH a subsidiary
named as the applicant on its applications, in AT. 2 more under the same name are not counted (printed in AU)
0 granted
3 published
Valneva SE its own name
named as the applicant on its applications, in FR
0 granted
3 published
VALNEVA SWEDEN AB a subsidiary
SE, as the owner printed on each patent
0 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jun 17, 202512,331,084Multivalent OspA polypeptides and methods and uses relating theretoPharmaceuticalsValneva Austria GmbH
Jun 10, 202512,324,831Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereofPharmaceuticalsValneva Austria GmbH
Feb 4, 202512,214,033Virus purificationPharmaceuticalsValneva SE
Jan 14, 202512,195,501Mutant fragments of OspA and methods and uses relating theretoPharmaceuticalsValneva Austria GmbH
Dec 10, 202412,162,909Subunit vaccine for treatment or prevention of a respiratory tract infectionPharmaceuticalsValneva SE
Dec 10, 202412,162,907Subunit vaccine for treatment or prevention of a respiratory tract infectionPharmaceuticalsValneva SE
Oct 1, 202412,102,673Zika virus vaccinePharmaceuticalsValneva Austria GmbH
Aug 6, 202412,053,518Method for rescuing and producing a virus in avian cellsPharmaceuticalsValneva SE
Jun 25, 202412,018,054Multivalent OspA polypeptides and methods and uses relating theretoPharmaceuticalsValneva Austria GmbH
Jun 18, 202412,011,477Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3PharmaceuticalsValneva SE
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0360191ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOFPharmaceuticalsValneva Austria GmbH
Jul 3, 20252025/0213667CLOSTRIDIUM DIFFICILE VACCINEPharmaceuticalsValneva Austria GmbH
May 29, 20252025/0171501A SUBUNIT VACCINE FOR TREATMENT OR PREVENTION OF A RESPIRATORY TRACT INFECTIONPharmaceuticalsValneva SE
Mar 27, 20252025/0101069MULTIVALENT OSPA POLYPEPTIDES AND METHODS AND USES RELATING THERETOPharmaceuticalsValneva Austria GmbH · patent 12,331,084 granted from it
Mar 6, 20252025/0073326METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS COMPRISING IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NSP3PharmaceuticalsValneva SE
Jan 16, 20252025/0018023Zika Virus VaccinePharmaceuticalsValneva Austria GmbH
Oct 31, 20242024/0358812HUMAN METAPNEUMOVIRUS COMBINATION VACCINEPharmaceuticalsValneva SE
Sep 5, 20242024/0293531INACTIVATED SARS-COV-2 VIRUS VACCINEPharmaceuticalsValneva Austria GmbH
Jun 6, 20242024/0181034HUMAN METAPNEUMO VIRUS VACCINEPharmaceuticalsValneva SE
Apr 4, 20242024/0108712ZIKA VIRUS VACCINEPharmaceuticalsValneva Austria GmbH · patent 12,102,673 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 12.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton VALN · research, not advice